Fixed drug eruption to sitagliptin by Mrinal Gupta & Anish Gupta
Gupta and Gupta Journal of Diabetes & Metabolic Disorders  (2015) 14:18 
DOI 10.1186/s40200-015-0145-2CASE REPORT Open AccessFixed drug eruption to sitagliptin
Mrinal Gupta1* and Anish Gupta2Abstract
Fixed drug eruption is a common adverse effect seen with various drugs notably antibiotics, antiepileptics and
non-steroidal anti-inflammatory drugs. Herein we report a case of Sitagliptin induced fixed drug eruption in a
46 year old female who developed circumscribed, erythematous macules all over the body within one week of
initiation of Sitagliptin. The lesions resolved with residual hyperpigmentation on cessation of the drug. The diagnosis
was confirmed by an oral provocation test which led to a reactivation of the lesions. To the best of our knowledge, this
is the first case of fixed drug eruption to Sitagliptin reported in the literature.
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Fixed drug eruption (FDE) is a common cutaneous ad-
verse effect seen with a wide array of drugs like antimicro-
bials, antiepileptics and non-steroidal anti-inflammatory
drugs. FDE is characterized by well circumscribed, ery-
thematous muco-cutaneous macules that can at times de-
velop as early as 30 minutes after exposure to the
causative drug, healing with residual hyperpigmentation
and recurring at the same site upon subsequent exposure
to the same drug. Sitagliptin is a novel antihyperglycemic
agent belonging to the class of dipeptidyl peptidase IV in-
hibitors, which is used as a second line drug for the man-
agement of type II diabetes mellitus [1]. Herein we report
a case of FDE due to Sitagliptin in a 46 year old female
which, to the best of our knowledge, is the first case to be
reported in the literature.Case presentation
A 46 year-old woman presented in our centre with a
three day history of multiple red colored skin lesions
which were progressive and were associated with itching
and burning sensation. On taking the detailed history, it
was revealed that the patient had been suffering from
type II diabetes mellitus for the past three years and was
being managed with tablet metformin 500 mg twice
daily, but one week prior to the onset of skin lesions the
patient was also started on tablet Sitagliptin 50 mg/day
by her physician in view of the poor glycemic control.* Correspondence: drmrinalgupta@yahoo.com
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tiple circumscribed, reddish lesions over the lips and
hands which were associated with burning sensation,
which over the next two days progressed to involve the
trunk and lower extremities. There was no history of
any other drug intake prior to the eruption or any simi-
lar lesions in the past. On muco-cutaneous examination,
multiple circumscribed erythematous and hyperpig-
mented round macules were present over the lips, trunk
and the extremities whereas the oral and genital mucosae
showed the presence of well defined erosions (Figure 1).
Nails and hair examination revealed no abnormality. La-
boratory tests, including full blood count and biochemis-
try profile including liver and renal functions, were within
normal limits, except for blood glucose, with a value of
167 mg/dl. A skin biopsy was performed and the histo-
pathological examination revealed a dense band like
lymphocytic infiltrate, perivascular inflammatory infiltrate,
eosinophils and increased pigment incontinence suggest-
ive of fixed drug eruption (Figure 2). At this junction, a
diagnosis of FDE was made and all the drugs were discon-
tinued and the patient was started on Prednisolone
40 mg/day and Glimepride. Five days after initiation of
oral corticosteroids, the lesions subsided with residual
hyperpigmentation. Two weeks later, oral provocation was
done, after taking informed consent, and initially metfor-
min was given in full therapeutic dose but no recurrence
was observed. After another two weeks, patient was ad-
ministered Sitagliptin 50 mg and within six hours of ad-
ministration, there was recurrence of lesions in the form
of itching and erythema over the residual pigmentedntral. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Fixed drug eruption involving the trunk and extremities.
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course of oral corticosteroids and antihistamines which
led to clearance of lesions. Causality assessment was car-
ried out using the Naranjo’s scale and the World Health
Organization (WHO)‑Uppsala Monitoring centre (UMC)
Criteria after which we came to a conclusion that Sitagliptin
was the “probable” (Naranjo’s score 6) cause of this ad-
verse drug reaction [2,3]. Keeping in view her medical
history and the nature of lesions, a diagnosis of FDE sec-
ondary to Sitagliptin was made and the patient was coun-
seled regarding further avoidance of the drug.
Discussion
Sitagliptin is a newly developed oral hypoglycemic drug
for the management of type II diabetes mellitus belong-
ing to the class of dipeptidyl peptidase (DPP)-IV inhibi-
tors, approved by the US Food and Drug Administration
in 2006. Apart from systemic adverse effects like hypo-
glycemia, gastrointestinal effects, pancreatitis, respiratory
side effects like nasopharyngitis and upper respiratory
tract infections, Sitagliptin has been reported to induce aFigure 2 Histopathology (H&E) showing band like inflammatory
infiltrate, perivascular infiltrate and pigment incontinence.wide array of cutaneous adverse effects including psoria-
siform eruption, maculopapular rash, Stevens Johnson
syndrome, toxic epidermal necrolysis, anaphylaxis, cuta-
neous vasculitis, bullous pemphigoid, photosensitivity
and angioedema on co-administration with ACE inhibi-
tors [1,4-7]. A thorough search of literature could not
reveal any case of FDE due to Sitagliptin till date.
FDE is a type of delayed hypersensitivity reaction me-
diated by CD8+ T-cells in which the causative drug acts
as a hapten, which induces sensitization and develop-
ment of sensitized CD8+ T-cells, which get activated on
re-exposure to the offending drug [8]. Although clinical
history remains the mainstay of diagnosis, patch tests
and drug challenge tests are also helpful and can be usedFigure 3 Increased erythema over pre-existing hyperpigmented
lesions after oral provocation test.
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have been found useful in the diagnosis of FDE espe-
cially when applied at the previously affected sites. Drug
challenge test are the most accurate diagnostic tool for
the diagnosis of FDE which can be performed either by
starting with a low dose of suspected drug followed by
gradual escalation or by starting with the full therapeutic
dose at once. A lymphocyte transformation test is a la-
boratory test for the diagnosis of delayed drug hypersen-
sitivity especially maculopapular drug rash, but have
been found useful in FDE also [9]. These tests are of im-
portance, both for the confirmation of diagnosis as well
as for the identification of causative drug. Discontinu-
ation of the offending drug forms the mainstay of treat-
ment and may be the only treatment required for mild
cases but severe cases may require topical and systemic
corticosteroids and antihistamines. Patient education
and counseling regarding the avoidance of the offending
drug or its derivatives to prevent recurrences constitute
an important aspect of management.
Conclusion
In conclusion, Sitagliptin is a new drug commonly being
used for the management of type II diabetes mellitus;
henceforth adverse effects caused by it are still not fully
known. Cutaneous adverse effects have been reported
with Sitagliptin but this is the first case of FDE reported
with it. The healthcare providers should be fully aware
of the various adverse effects of the drug in order to
prevent recurrences and for rapid diagnosis and proper
management of the same.
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